Revista de la Facultad de Medicina Humana
Volume 20

Issue 1

Article 2

2020

Biopsia Líquida en Oncología: ¿Mito o Realidad?
Antonio Russo
Department of Surgical, Oncological and Oral Sciences University of Palermo, Italy.,
antonio.russo@usa.net

Antonio Galvano

Follow this and additional works at: https://inicib.urp.edu.pe/rfmh
Part of the Health Information Technology Commons, and the Public Health Commons

Recommended Citation
Russo, Antonio and Galvano, Antonio (2020) "Biopsia Líquida en Oncología: ¿Mito o Realidad?," Revista de
la Facultad de Medicina Humana: Vol. 20: Iss. 1, Article 2.
Available at: https://inicib.urp.edu.pe/rfmh/vol20/iss1/2

This Editorial is brought to you for free and open access by INICIB-URP. It has been accepted for inclusion in
Revista de la Facultad de Medicina Humana by an authorized editor of INICIB-URP.

Russo and Galvano: Biopsia Líquida en Oncología: ¿Mito o Realidad?

Rev. Fac. Med. Hum. January 2020;20(1):8-9.
DOI 10.25176/RFMH.v20i1.2643

ISSN Version Online: 2308-0531

Faculty of Human Medicine URP

EDITORIAL

LIQUID BIOPSY IN ONCOLOGY: MYTH OR REALITY?
BIOPSIA LÍQUIDA EN ONCOLOGÍA: ¿MITO O REALIDAD?

EDITORIAL

Antonio Russo1, Antonio Galvano1

One of the most relevant challenge in oncology would be the ability to deeply know tumoral genetic aspects
through technological innovation and translational research to be finally able to personalize oncological
treatment based not only on classical patient’s clinical characteristics but also on its tumoral genetic portrait.
In the last few years, many studies showed that to select cancer patients for a specific drug on the basis of
specific genetic alterations could determine the greatest potential clinical benefit for a longer time, compared
to treatment with the classic cytotoxic chemotherapy. Thus, oncology moves from the classic "one size fits
all" approach, which provided classic chemotherapy agents on the basis of the cancer primary site and its
histological type, to a new classification based on the tumor molecular profile. The characterization of the
genetic alterations of the tumors, and the understanding of the complex interaction between the molecules
of the same network represents, therefore, the rationale on which precision medicine is based. These advances
have been made possible by the recent development of new technologies, such as next generation sequencing
(NGS) or massive parallel sequencing (MPS), which allow the sequencing of larger gene portions compared
to previous technologies, with reduced times and an increase in analytical sensitivity. The potential of these
platforms in clinical practice is linked both to the analysis of cells on tumor tissue and to the analysis of
circulating tumor DNA (ctDNA) contained in circulating free DNA (cell free DNA, cfDNA) which can be isolated
from peripheral blood and biological fluids (liquid biopsy), instead of neoplastic tissue. However, in complex
tumor biology, it is not enough to identify a genetic alteration to be sure that it can represent a predictive
factor of response or therapeutic resistance: the presence of a genetic alteration and the availability of a drug
directed against that alteration are only preconditions for effectiveness. There are, in fact, "driver" mutations
and "passenger" mutations; and although many neoplasms depend on a single oncogene for their growth and
survival (according to the theory of "oncogene addiction" or "oncogene driver"), the selective pressure exerted
by medical treatment on the network of intracellular signals can determine the hyperactivation of compensating
pathways and alternative pathways that result in a suboptimal modulation of the target pathway. Another
critical point that can represent an obstacle to precision medicine is tumor heterogeneity: the tumor genome
dynamically evolves over time and accumulates genetic alterations in different cell sub-clones. This translates
into an intratumoral heterogeneity both spatially, i.e. between the primary tumor and the metastatic sites (or,
even, within the tumor nodule itself), and in a temporal heterogeneity, or the bio-molecular characteristics of
the neoplasm may vary in time. In this perspective, liquid biopsy could represent a useful tool for obtaining a
dynamic picture of the molecular evolution of the disease. The main field of application of liquid biopsy to date
is represented by the identification of predictive factors in patients with advanced disease and is currently used
in clinical practice for the mutational analysis of the Epidermal Growth Factor Receptor (EGFR) and/or T790M
gene in patients with Advanced non-small cell lung cancer (NSCLC). In particular, liquid biopsy can routinely
replace standard tissue biopsy if tissue biopsy is technical impossible at diagnosis of advanced NSCLC or in
patients progressing after a first (gefitinib or erlotinib) or second (afatinib) generation tyrosine-kinase inhibitors
(TKI) in order to determine the T790M mutational status that is considered predictive for third generation TKI
(osimertinib) efficacy. The effort of the scientific community is now to transfer the genomic and proteomic
knowledge of basic research to clinical practice, to provide clinically relevant information for choosing a
personalized treatment, with a view to precision medicine. In fact, although the liquid biopsy is able to more fully
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represent the molecular heterogeneity of the disease
compared to the tissue biopsy, potentially containing
tumor DNA deriving from the different areas of the
same tumor, in the presence of tumor heterogeneity,
it provides little information on the representativeness
in the context of the tumor of the biomarker identified.
Other potential limitations of liquid biopsy could
be related to false negative (Insufficient DNA shed
into plasma, insufficient sensitivity in older assays) or
false positive (wide time interval between tissue and
sample sampling, white blood cells contamination
and tumor heterogeneity) conditions. Finally, the
new diagnostic-therapeutic approach to neoplasms,
which integrates clinical-pathological criteria with
molecular analyzes, is also reflected in clinical trial
designs: precision medicine has meant that clinical
trials relating to new drugs with a molecular target,
have become difficult to conduct through the classic
designs of controlled clinical studies: the classification
based on the molecular profile causes a segmentation
of the neoplasms into numerous molecular subtypes,
which include subgroups of few patients. Therefore,
new designs of clinical trials have been developed, such
as the "Basket" and "Umbrella trials", in which patients

are recruited on the basis of the genetic and molecular
characteristics of the neoplasm, with the aim of giving
treatment only to patients potentially more responsive,
reducing the use of ineffective and in any case toxic
drugs, as well as the development time of new drugs and
the associated costs. These trials resulted in two recent
“agnostic” approval for larotrectinib and pembrolizumab
for all patients who carried molecular alteration on NTRK
fusion gene or who carried microsatellite instability
respectively, irrespective of the primary tumor site. These
represented the paradigm of a new era in oncology in
which every patient will receive a tailored new generation
therapy according to its own tumor genotype. Of
course, as it is easy to imagine, these in-depth analyzes
of the tumor genome will provide an always greater
amount of genetic information for many of which an
adequate cancer treatment is not yet available. It is for
these reasons that the institutional tumor boards must
recruit molecular biologists and pathologists which
will therefore constitute the so-called molecular tumor
boards whose usefulness will be essential for the correct
interpretation of the bioinformatic data in order to
determine the most appropriate therapeutic choice for
every oncological patient.
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